Lisa Egbuonu-Davis Sells 2,546 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) Director Lisa Egbuonu-Davis sold 2,546 shares of Phreesia stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $9.53, for a total value of $24,263.38. Following the sale, the director directly owned 38,316 shares of the company’s stock, valued at approximately $365,151.48. This trade represents a 6.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Phreesia Price Performance

Shares of Phreesia stock opened at $9.96 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $615.94 million, a PE ratio of 66.43 and a beta of 0.91. The business’s 50-day moving average price is $9.35 and its 200-day moving average price is $11.99. Phreesia, Inc. has a 12 month low of $7.77 and a 12 month high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $130.94 million for the quarter, compared to analysts’ expectations of $130.08 million. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.Phreesia’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.07) EPS. Sell-side analysts forecast that Phreesia, Inc. will post 0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PHR shares. KeyCorp lowered their price objective on shares of Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Piper Sandler lowered shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a report on Thursday, May 28th. Truist Financial lifted their target price on shares of Phreesia from $11.00 to $12.00 and gave the stock a “hold” rating in a research report on Thursday, May 28th. Mizuho lowered their price target on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th. Finally, Robert W. Baird restated a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Nine research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $16.65.

Institutional Trading of Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Phreesia by 8.3% in the third quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock worth $134,177,000 after buying an additional 437,462 shares during the period. Greenhouse Funds LLLP boosted its position in Phreesia by 16.8% during the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares during the period. SG Americas Securities LLC purchased a new stake in Phreesia during the 4th quarter valued at $1,203,000. Tudor Investment Corp ET AL purchased a new stake in Phreesia during the 3rd quarter valued at $4,173,000. Finally, King Luther Capital Management Corp grew its holdings in Phreesia by 172.6% in the 4th quarter. King Luther Capital Management Corp now owns 268,314 shares of the company’s stock worth $4,540,000 after acquiring an additional 169,900 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analysts are still viewing Phreesia as a “Hold,” suggesting the stock’s long-term outlook is not being broadly written off by Wall Street. Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of “Hold” by Brokerages
• Neutral Sentiment: A director, Lisa Egbuonu-Davis, sold 2,546 shares in a pre-arranged Rule 10b5-1 transaction. While insider sales can attract attention, the filing indicates it was scheduled in advance rather than a discretionary move. Director stock sale disclosure
• Negative Sentiment: Phreesia is facing repeated investor alerts from law firms about a securities fraud class action, which may keep pressure on the stock until the deadline passes and more clarity emerges. Phreesia investigation alert
• Negative Sentiment: Several firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, The Gross Law Firm, the Schall Law Firm, and DJS Law Group, are urging investors to participate in the class action before the July 13 deadline, reinforcing the legal risk narrative. Phreesia sued for securities law violations

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.